Cell Therapeutics, Inc. PAC326 (PERSIST 2) A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Cancer - Hematology/ Blood
Principal Investigator: Vrushali S Dabak, MD
This study will compare the safety and efficacy of two dose schedules (either once-daily or twice-daily) of pacritinib versus best available therapy in patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis.
Diagnosis of intermediate -1 or -2 or high-risk Myelofibrosis; at least 6 months from prior splenic irradiation; at least 1-4 weeks since prior myelofibrosis therapy, including any erythropoietic or thrombopoietic agent; able and willing to undergo frequent MRI or CT assessments and complete symptom assessments using a patient-reported outcome instrument.